Aldafermin improves fibrosis in patiants with NASH

NGM Biopharmaceuticals, Inc. (USA) presented on August, 2020, the results of the phase 2 trial which met its primary endpoint, achieving a statistically significant reduction in liver fat content, robust fibrosis improvement, and resolution of NASH, with a favorable safety profile.


For detailed information, see the below URL.


It has been reported that administration of Aldafermin, an analog of FGF19, improves NASH and fatty liver-derived fibrosis.
The results are likely to further accelerate planning for Aldafermin's Phase 3 trial.